标题：复合乳酸菌胶囊联合蒙脱石散治疗小儿腹泻的疗效及对血清 IL-6、IL-17、免疫球蛋白的影响

      作者：梁银，田恬，赵红，景芳丽    西安国际医学中心医院儿内科，陕西 西安 710065

      卷次： 2023年34卷1期

      【摘要】 目的 观察复合乳酸菌胶囊联合蒙脱石散治疗小儿腹泻的疗效，探讨其对患儿血清白细胞介素(IL)-6、IL-17、免疫球蛋白(Ig)的影响。方法 选择2020年1月至2021年12月西安国际医学中心医院儿内科收治的100例腹泻患儿为研究对象，按照随机数表法分为观察组和对照组各50例。对照组患儿在常规治疗基础上给予蒙脱石散治疗，观察组患儿在对照组基础上联合复合乳酸菌胶囊治疗，两组患儿均持续治疗7 d。比较两组患儿的临床疗效，以及治疗前、治疗3 d及7 d后的大便次数、大便性状评分，治疗前及治疗7 d后血清 IL-6、IL-17、IgA、IgG的变化及治疗期间的不良反应发生情况。结果 观察组患儿的治疗总有效率为 94.00%，明显高于对照组的78.00%，差异有统计学意义(P<0.05)；治疗 3 d后，观察组患儿的大便次数、大便性状评分分别为(2.68±0.41)次/d、(1.11±0.18)分，明显低于对照组的(3.21±0.55)次/d、(1.36±0.15)分，止泻时间为(3.28±0.56) d，明显短于对照组的(4.19±0.67) d，差异均有统计学意义(P<0.05)；治疗 7 d后，观察组患儿血清 IL-6、IL-17水平分别为(8.20±1.75) pg/mL、(10.58±2.13) pg/mL，明显低于对照组的(11.18±2.03) pg/mL、(13.61±2.46) pg/mL，IgA、IgG分别为(1.89±0.22) g/L、(14.02±1.54) g/L，明显高于对照组的(1.63±0.17) g/L、(11.36±1.29) g/L，差异均有统计学意义(P<0.05)；观察组和对照组患儿不良反应总发生率分别为6.00%、4.00%，差异无统计学意义(P>0.05)。结论 复合乳酸菌胶囊联合蒙脱石散治疗小儿腹泻可缩短止泻时间，且有助于改善血清 IL-6、IL-17、IgA、IgG水平，疗效显著，值得临床推广。
      【关键词】 腹泻；蒙脱石散；复合乳酸菌胶囊；白细胞介素；免疫球蛋白；疗效；不良反应
      【中图分类号】 R725.7 【文献标识码】 A 【文章编号】 1003—6350（2023）01—0059—04

Clinical efficacy of compound lactobacillus capsule combined with montmorillonite powder in the treatment ofinfantile diarrhea and its influence on serum IL-6, IL-17, and immunoglobulin.
LIANG Ying, TIAN Tian, ZHAOHong, JING Fang-li. Department of Pediatrics, Xi'an International Medical Center Hospital, Xi'an 710065, Shaanxi,CHINA
【Abstract】 Objective To observe the efficacy of compound lactobacillus capsule combined with montmorillon-ite powder in the treatment of children with diarrhea, and to explore its effect on serum interleukin (IL)-6, IL-17, immu-noglobulin (Ig) in children. Methods A total of 100 children with diarrhea admitted to Department of Pediatrics, Xi'anInternational Medical Center Hospital from January 2020 to December 2021 were selected as the research objects. Ac-cording to the random number table, they were divided into an observation group and a control group, with 50 cases ineach group. Children in the control group were given montmorillonite powder treatment on the basis of conventionaltreatment, and those in the observation group were given compound lactobacillus capsule on the basis of the treatment inthe control group, both for 7 days. The clinical efficacy, the changes of tool frequency and stool trait score before treat-ment and at 3 d, 7 d after treatment, the serum IL-6, IL-17, IgA, and IgG before treatment and at 7 d after treatment, andincidence of adverse reactions during treatment were compared between the two groups. Results The total effectiverate in the observation group was 94.00%, which was significantly higher than 78.00% of the control group (P<0.05). At3 days after treatment, the stool frequency and stool trait score in the observation group were (2.68±0.41) times/d and(1.11±0.18) minutes, which were significantly lower than (3.21±0.55) times/d and (1.36±0.15) minutes of the controlgroup, and antidiarrheal time was (3.28±0.56) d, which was significantly shorter than (4.19±0.67) days of the controlgroup; the differences were statistically significant (P<0.05). At 7 days after treatment, the serum IL-6 and IL-17 levelsin the observation group were (8.20±1.75) pg/mL and (10.58±2.13) pg/mL, which were significantly lower than (11.18±2.03) pg/mL and (13.61±2.46) pg/mL of the control group; the IgA and IgG were (1.89±0.22) g/L and (14.02±1.54) g/L,which were significantly higher than (1.63±0.17) g/L and (11.36±1.29) g/L of control group; the differences were statisti-cally significant (P<0.05). The total incidence of adverse reactions in the observation group and the control group was